Addus HomeCare (NASDAQ:ADUS) Receives “Outperform” Rating from Macquarie

Macquarie reissued their outperform rating on shares of Addus HomeCare (NASDAQ:ADUS) in a research note issued to investors on Friday morning, Benzinga reports. Macquarie currently has a $139.00 target price on the stock.

Several other analysts have also recently commented on ADUS. Royal Bank of Canada restated an outperform rating and issued a $141.00 target price on shares of Addus HomeCare in a research note on Tuesday, September 3rd. Stephens reissued an overweight rating and set a $138.00 price target on shares of Addus HomeCare in a research note on Tuesday, August 6th. TD Cowen raised their price objective on Addus HomeCare from $128.00 to $137.00 and gave the company a buy rating in a research note on Thursday, August 8th. Oppenheimer boosted their target price on Addus HomeCare from $140.00 to $145.00 and gave the stock an outperform rating in a research report on Monday, September 23rd. Finally, StockNews.com cut Addus HomeCare from a strong-buy rating to a buy rating in a research report on Sunday, July 7th. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of Moderate Buy and an average target price of $131.38.

Addus HomeCare Trading Up 0.9 %

Shares of ADUS opened at $131.81 on Friday. The company’s 50 day simple moving average is $129.83 and its 200-day simple moving average is $117.54. The firm has a market cap of $2.39 billion, a PE ratio of 32.71, a price-to-earnings-growth ratio of 2.33 and a beta of 1.04. Addus HomeCare has a 12-month low of $78.35 and a 12-month high of $136.12.

Addus HomeCare (NASDAQ:ADUS) last posted its quarterly earnings data on Monday, August 5th. The company reported $1.35 EPS for the quarter, beating analysts’ consensus estimates of $1.21 by $0.14. Addus HomeCare had a net margin of 6.18% and a return on equity of 9.81%. The company had revenue of $286.90 million for the quarter, compared to analyst estimates of $284.90 million. During the same period in the previous year, the business posted $0.94 earnings per share. Addus HomeCare’s quarterly revenue was up 10.4% on a year-over-year basis. As a group, equities research analysts forecast that Addus HomeCare will post 4.58 EPS for the current fiscal year.

Insider Activity at Addus HomeCare

In other Addus HomeCare news, Director Esteban Lopez sold 500 shares of the business’s stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $127.50, for a total transaction of $63,750.00. Following the transaction, the director now owns 3,366 shares in the company, valued at $429,165. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, EVP Michael D. Wattenbarger sold 21,917 shares of Addus HomeCare stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $133.29, for a total value of $2,921,316.93. Following the completion of the transaction, the executive vice president now owns 7,215 shares in the company, valued at approximately $961,687.35. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Esteban Lopez sold 500 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $127.50, for a total value of $63,750.00. Following the transaction, the director now owns 3,366 shares in the company, valued at $429,165. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 22,917 shares of company stock worth $3,050,082. 4.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Addus HomeCare

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Creative Planning increased its position in shares of Addus HomeCare by 5.8% in the third quarter. Creative Planning now owns 4,910 shares of the company’s stock worth $653,000 after acquiring an additional 267 shares in the last quarter. Oliver Luxxe Assets LLC grew its holdings in shares of Addus HomeCare by 244.8% during the third quarter. Oliver Luxxe Assets LLC now owns 16,512 shares of the company’s stock valued at $2,197,000 after buying an additional 11,723 shares in the last quarter. Redhawk Wealth Advisors Inc. acquired a new stake in Addus HomeCare during the 3rd quarter worth about $922,000. Inspire Investing LLC grew its stake in Addus HomeCare by 3.3% during the 3rd quarter. Inspire Investing LLC now owns 3,111 shares of the company’s stock valued at $414,000 after acquiring an additional 100 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in shares of Addus HomeCare by 25.7% in the third quarter. GAMMA Investing LLC now owns 935 shares of the company’s stock worth $124,000 after purchasing an additional 191 shares in the last quarter. Institutional investors own 95.35% of the company’s stock.

About Addus HomeCare

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.